Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE randomized phase III trial (GFPC 01-2020).

Fiche publication

Date publication

octobre 2026

Journal

Annals of oncology : official journal of the European Society for Medical Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr SCHOTT Roland

Tous les auteurs :
Descourt R, Mogenet A, Consigny M, Bernardi M, Corre R, Bylicki O, Auliac JB, Vergnenègre A, Ricordel C, Pinsolle J, Wislez M, Pedrono M, Veillon R, Falchero L, Guisier F, Hauss PA, Bizieux-Thaminy A, Hominal S, Madroszyk A, Curcio H, Schott R, Huchot E, Besse B, Locher C, Le Treut J, Willemin MC, François G, Uguen A, Pérol M, Chouaïd C, Greillier L, Decroisette C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42927854

Résumé

Pembrolizumab, alone or combined with platinum-based chemotherapy, is a standard first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) without actionable oncogenic alterations and with high programmed death-ligand 1 (PD-L1) expression. We conducted a head-to-head comparison of these two treatment strategies.